To get from point A of a stem cell discovery to point B of a patient actually receiving a treatment based on that discovery is a long and non-linear road, which requires biotech company research. Stem cell biotech companies including publicly traded companies are an integral part of the field making that journey. How those …
The path to the clinic is a slow and arduous activity, frustrating not only to the researcher and patient, but investors and biotech companies. Successful clinical translation of technologies requires a balance of science, streamlined translation and funding. To develop fantastic science and then realise the most important components cannot be adapted to the clinical …
Biotech Talks #ISSCR2015: StemCells Inc, Semma, ViaCyte, & Le Blanc Read More »
Last week I attended Biotech & the Ethical Imagination (BEINGS 2015), the summit I previewed on this blog back in early May. It many ways the summit lived up to its lofty ambitions. Steven Pinker kicked off the event by emphasizing the power and importance of biomedical research, noting that almost everyone is affected by …
Recap of BEINGS 2015 Meeting by Aaron Levine: Shaping Future of Cellular Biotech Read More »
Later this May, I will attend and participate in Biotechnology and the Ethical Imagination (BEINGS 2015). This is an exciting and experimental summit that will focus on advances in cellular biotechnology – including both stem cell science and synthetic biology. The meeting is premised on the idea that the implications of increasing biotechnology power are …
Biotechnology & the Ethical Imagination – A Preview of BEINGS summit Read More »
A new biotech startup, Semma Therapeutics, announced that it seeks to fight diabetes via translating technology from the lab of Doug Melton at Harvard to the clinic. Update: Note that the firm was recently acquired by Vertex. Another major player in cell therapy-based arena for Diabetes is most likely good news for patients. Quoted in the Boston …
New biotech Semma Therapeutics stem cell diabetes arena Read More »
The below is an excerpt from my book, Stem Cells: An Insider’s Guide. I hope you enjoy this excerpt and the book, which I think is a really good deal at under $27 paperback or under $17 for E-book version. Having our innovation and ethics too In the stem cell field you can have it …
Book Excerpt: Stem Cell For-Profit Good Citizen Biotechs Read More »
What the heck is going on with Intellicell Biosystems, Inc. (SVFC, also SVFCE), a stem cell corporation run by Dr. Steven Victor? Why are some on Wall Street seeming so bullish on the company lately? What’s the real story and the facts? What is the key background on this company? Wall Street has been buying …
Wall Street Weirdness Over Stem Cell Biotech Intellicell (SVFC) Read More »
For the second year in a row (see awards 2011), Advanced Cell Technology (ACT; stock symbol ACTC) is my stem cell biotech of the year. Their trials for different forms of macular degeneration (here and here and here) are progressing well and as a stem cell scientist I really appreciate the fact they are publishing their …
Stem cell biotech of the year 2012: Advanced Cell Technology (ACTC) Read More »
Advanced Cell Technology (ACT; stock symbol ACTC) announced that it has secured $35 million in funding from investment company, Lincoln Park Capital. The press release quotes CEO Gary Rabin: “We are most pleased about this financing agreement, as it has a number of notable benefits for the company,” commented Gary Rabin, chairman and CEO of …
Stem Cell Biotech Advanced Cell Technology (ACT) gets $35 million Read More »
When I was at the recent World Stem Cell Summit, I had the opportunity to meet a ton of people from all different walks of life including other scientists in academia, folks in the biotech/pharma industry, and many inspiring patient advocates. A number of people were curious about my view on how the stem cell-related …
Update on stem cell biotechs: an ethical investment, but risky and requiring patience. Read More »